Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase 1 Study of S-3304 in Patients With Solid Tumors


A Phase 1 Study of S-3304 in Patients With Solid Tumors




To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

Study Status: Active, not recruiting


Condition Intervention Phase
Solid Tumors Drug: S-3304 Phase 1

Verified by Shionogi November, 2003

Sponsored by: Shionogi
Information provided by: Shionogi identifier: NCT00033215

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site